Advertisement

Topics

Latest Biotechnology Products NewsRSS

20:56 EST 22nd November 2017 | BioPortfolio

Alder Biopharmaceuticals Inc ALDR Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryAlder Biopharmaceuticals Inc Alder is a biopharmaceutical company which develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushing's disease and autoimmune and inflammatory diseases. The company uses technologies such as the antibody selection system and novel mab xpress antibody production system. Its pipeline products include clazakizumab and ep...

Alder BioPharmaceuticals® to Present at 29th Annual Piper Jaffray Healthcare Conference

BOTHELL, Wash., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the 29th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET on Wednesday, November 29, 2017 in New York. The presentation will feature a business...

Aeglea BioTherapeutics Inc AGLE Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryAeglea BioTherapeutics Inc Aeglea BioTherapeutics, formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company's product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in t...

Biosimilars and BiologicsEurope Market Status and Trend Report 20132023 [Report Updated: 09102017] Prices from USD $3480

Report SummaryBiosimilars and BiologicsEurope Market Status and Trend Report 20132023 offers a comprehensive analysis on Biosimilars and Biologics industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answer...

Navidea Biopharmaceuticals to Present at LD Micro 10th Annual Main Event

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the LD Micro 10th Annual Main Event in Los Angeles, CA on December 5-7, 2017. Jed Latkin, Chief Financial Officer and Chief Operating Officer of Navidea, will be giving a pr...

RegeneRx Biopharmaceuticals Inc RGRX Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryRegeneRx Biopharmaceuticals Inc RegeneRx is a biopharmaceutical company that provides clinical stage drug development solutions. The company offers clinical trials, science and discovery and business development services. Its business development services include clinical development and commercialization interests in desired pharmaceutical therapeutic fields for suitable infrastructure, ex...

XTL Biopharmaceuticals Ltd XTLB Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryXTL Biopharmaceuticals Ltd XTL is a biopharmaceutical company that offers acquisition, development and commercialization of pharmaceutical products and latestage pharmaceutical product candidates for the treatment of medical needs. The company's pipeline products comprise hCDR1 peptide and recombinant erythropoietin rHuEPO. Its hCDR1 peptide is used for the treatment of systemic lupus eryth...

ESMO Celebrates Successful Completion Of 3rd ESMO Asia Congress In Singapore

SINGAPORE -- (Marketwired) -- 11/21/17 -- The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, has successfully concluded the ESMO Asia 2017 Congress in Singapore. Since its inauguration in 2015, ESMO Asia Congress has garnered attention and significant interest from cancer experts and researchers, not only in Asia, but around the world. T...

Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference

CARMIEL, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) announced today two-year results from the phase I/II open-label extension clinical trial of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease will be presented at the New Horizons in Fabry Disease Conference taking place November 24-25 in Prague, Czech Republic. ...

Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®

ONTRUZANT® is the industry’s first biosimilar referencing Herceptin® i (trastuzumab) to receive marketing authorization from the European Commission Samsung Bioepis sets an industry record by obtaining European regulatory approval for four biosimilars in just two years Samsung Bioepis Co., Ltd. today an...

Cytena – single cells on demand

Cytena – single cells on demand Clonal cell line development is a crucial step in various applications including generating biopharmaceuticals (eg. monoclonal antibodies). Current workflows in cell line development have major drawbacks such as missing proof of clonality, inefficient single-cell … Continue reading → Cet article Cytena – single cells on demand est apparu en premier s...

Adalimumab and trastuzumab biosimilars approved in South Korea

South Korean biosimilars maker Samsung Bioepis announced on 9 November 2017 that it had received marketing approval for its biosimilar version of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) from Korea’s Ministry of Food and Drug Safety (MFDS). The news follows another announcement by the company on 22 September 2017 that it had also gained approval for its adalimumab bios...

Opportunities and challenges for biosimilars in oncology

The rapid increase in healthcare costs, particularly for cancer drugs, has had a major impact on providers, practices, payers and patients, according to Dr Gary Lyman of the Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA [1, 2].

UK launches campaign to promote research on biosimilars

A new campaign launched by the UK’s National Institute for Health Research (NIHR) aims to unlock the potential benefits of biosimilars in the National Health Service (NHS) through clinical trials.

CBI’s 13th Biosimilars Summit 2018

CBI’s 13th Biosimilars Summit 23−24 January 2018 Alexandria, VA, USA

Biosimilars poised to bring savings — if they get to launch

David SalazarEven as more approvals roll in and industry officials talk about how biosimilars will bring significant savings in the coming decade, there is a concern that regulatory and reimbursement hurdles could prevent the industry from realizing the full savings of the less-expensive alternative to biologics. read more

Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017

FREMONT, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Michael Mulroy, President and Chief Executive Officer, will present at the Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel in New York City. Asterias’ presentation is scheduled for...

Provectus Biopharmaceuticals Inc PVCT Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryProvectus Biopharmaceuticals Inc Provectus, formerly Provectus pharmaceuticals, Inc. is a biopharmaceutical company that develops pharmaceuticals for oncology and dermatology indications. The company's pipeline products include PV10 for recurrent melanoma, PV10 for metastatic liver cancer and PV10 for recurrent breast cancer. It offers PH10 for psoriasis and PH10 for atopic dermatitis. Prov...

Schnell Biopharmaceuticals Inc 003060 Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummarySchnell Biopharmaceuticals Inc Schnell, formerly Korea Schnell Pharma Co., Ltd. is a healthcare company that offers agents and antibiotics. The company provides pharmaceutical products including amino acid infusion agents and antibiotics. Its products portfolio includes antibiotics, infusions, containing amino acid, vitamin and hepatic protect infusions; gastrointestinal agents, comprising ...

New data reinforces clinical basis for switching to Sandoz biosimilar medicines

Novartis International AG / New data reinforces clinical basis for switching to Sandoz biosimilar medicines . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adal...

Biosimilars and BiologicsGlobal Market Status and Trend Report 20132023 [Report Updated: 09102017] Prices from USD $2480

Report SummaryBiosimilars and BiologicsGlobal Market Status and Trend Report 20132023 offers a comprehensive analysis on Biosimilars and Biologics industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answer...

#jobs #lifescience Covance UK: Assay Development Scientist – Harrogate, UK

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Covance UK: Assay Development Scientist – Harrogate, UK . competitive: Covance UK: We are currently recruiting for an Assay Development Scientist for our Biosimilars team. Harrogate, North Yorkshire … Continue reading → Cet article #jobs #lifescience Covance ...

Asterias Biotherapeutics Reports Third Quarter Financial Results and Recent Developments

- Continues to execute on key clinical programs and streamline cost structure - - Conference call and webcast today, November 14, at 4:30 p.m. ET - FREMONT, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today reported financial and operational results for the quarte...

Global and Asia Thymidine Market Status and Future Forecast 20132023 [Report Updated: 25102017] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...

BrightPath Biotherapeutics Co Ltd 4594 Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryBrightPath Biotherapeutics Co Ltd BrightPath Biotherapeutics formerly known as GreenPeptide Co Ltd is a biopharmaceutical venture company that develops novel cancer immunotherapies. The company operates on drug discovery research and early clinical development of cancer immunotherapy; conducts earlyphase clinical trials; and develops, manufactures, and launches the drugs as commercial produ...

Quick Search
Advertisement
 

review and buy Biotechnology Products market research data and corporate reports here